EntryPoint Capital LLC Acquires Shares of 9,040 Twist Bioscience Co. (NASDAQ:TWST)

EntryPoint Capital LLC acquired a new position in Twist Bioscience Co. (NASDAQ:TWST) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,040 shares of the company’s stock, valued at approximately $420,000.

Several other large investors also recently made changes to their positions in the business. Massachusetts Financial Services Co. MA lifted its position in Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares in the last quarter. Barclays PLC lifted its position in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares in the last quarter. FMR LLC grew its stake in shares of Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets raised its position in Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after purchasing an additional 21,357 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TWST. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. TD Cowen reissued a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Stock Down 1.5 %

Shares of NASDAQ TWST opened at $44.25 on Wednesday. The firm has a 50 day moving average price of $45.45 and a 200 day moving average price of $45.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The stock has a market cap of $2.64 billion, a P/E ratio of -13.09 and a beta of 2.15. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.75) EPS. Analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the transaction, the insider now owns 112,221 shares of the company’s stock, valued at approximately $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,799 shares of company stock worth $1,593,944 over the last ninety days. 3.01% of the stock is currently owned by corporate insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.